Aclaris Therapeutics to Announce Third Quarter 2018 Financial Results on November 6, 2018
October 29 2018 - 4:01PM
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led
biopharmaceutical company committed to identifying, developing, and
commercializing innovative therapies to address significant unmet
needs in aesthetic and medical dermatology and immunology, will
report financial results for third quarter 2018 on Tuesday,
November 6, 2018 after U.S. financial markets close.
Management will conduct a conference call at 5:00 PM
ET that day to discuss the Company’s financial results and
provide a general business update. A live webcast of the event
can be accessed on the Events and Presentations page on the
Investors section of the Aclaris website at
http://www.aclaristx.com/events-and-webcasts. A replay of the
webcast will be archived on the Aclaris website following the
event.
To participate on the live call, please dial (844) 776-7782
(domestic) or (661) 378-9535 (international), and reference
conference ID 7694929 prior to the start of the
call.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led
biopharmaceutical company focused on identifying, developing, and
commercializing innovative therapies to address significant unmet
needs in aesthetic and medical dermatology, and immunology.
Aclaris’ focus on market segments with no FDA-approved medications
or where treatment gaps exist has resulted in the first
FDA-approved treatment for raised seborrheic keratoses and several
clinical programs to develop medications for the potential
treatment of common warts, alopecia areata, and vitiligo. For
additional information, please visit www.aclaristx.com and follow
Aclaris on LinkedIn.
Aclaris ContactMichael Tung, M.D.Senior Vice President Corporate
Strategy/Investor Relations484-329-2140mtung@aclaristx.com
Media ContactSheila KennedyVice President, Corporate
Communications484-321-5559media@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jul 2023 to Jul 2024